Oragenics Inc. (NYSE American: OGEN) provided a shareholder update today, highlighting progress in its Phase IIa clinical trial of ONP-002 for concussion and mild traumatic brain injury (mTBI). The company reported that patient enrollment and dosing are actively underway across multiple sites in Australia. In addition, Oragenics is advancing U.S. regulatory preparations, targeting a Type C FDA meeting request in the second quarter and an Investigational New Drug (IND) submission by year-end 2026.
The update also disclosed a letter of intent to pursue licensing of a complementary CNS-related medical device, signaling a strategic expansion beyond its lead therapeutic candidate. Oragenics reported a cash balance of $6.1 million as of March 31, 2026, which is expected to fund operations into the near term.
ONP-002 is being developed as a potential first-in-class treatment for concussion and mTBI, utilizing the company's proprietary intranasal delivery technology. This platform is designed to bypass the blood-brain barrier and deliver therapeutics directly to the brain, with potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders.
The company's progress in Australia is a critical step toward generating clinical data that could support further development and regulatory approval in the U.S. Oragenics plans to follow the Australian Phase IIa trial with U.S. Phase 2b studies. The Type C FDA meeting will be used to discuss the development plan and align on requirements for the IND submission.
According to the press release, the full shareholder update is available at https://ibn.fm/tEk2C. Oragenics is a clinical-stage biotechnology company focused on brain-targeted therapeutics. More information about the company and its pipeline can be found at oragenics.com.
The announcement underscores Oragenics' commitment to addressing significant unmet medical needs in neurological care. With a robust cash position and a clear regulatory roadmap, the company is positioning itself to advance its lead candidate while exploring new opportunities in the CNS space. The letter of intent for a medical device licensing deal further diversifies its approach to neurological disorders.
Investors and stakeholders are encouraged to monitor the company's newsroom for ongoing updates at https://ibn.fm/OGEN.
